Limits...
The effect of intravitreal bevacizumab on ocular blood flow in diabetic retinopathy and branch retinal vein occlusion as measured by laser speckle flowgraphy.

Nitta F, Kunikata H, Aizawa N, Omodaka K, Shiga Y, Yasuda M, Nakazawa T - Clin Ophthalmol (2014)

Bottom Line: In the BRVOME group, there was no significant change in MBR in the retinal artery, retinal vein or ONH, but choroidal MBR decreased significantly (P=0.04).In the DME group, the MBR in the retinal artery, retinal vein, ONH, and choroid decreased significantly (P=0.02, P=0.04, P<0.001, and P=0.04, respectively).IVB had a suppressive effect on circulation in eyes with DME but not in those with BRVOME.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.

ABSTRACT

Background: This study evaluated the effect of intravitreal injection of bevacizumab (IVB) on macular edema associated with diabetic retinopathy (DME) or branch retinal vein occlusion (BRVOME) using laser speckle flowgraphy.

Methods: A comparative interventional study of 25 eyes from 22 patients with macular edema (DME group: 12 eyes; BRVOME group: 13 eyes) who underwent IVB. Mean blur rate (MBR) was measured in the retinal artery, retinal vein, optic nerve head (ONH), and choroid before and after IVB.

Results: In the BRVOME group, there was no significant change in MBR in the retinal artery, retinal vein or ONH, but choroidal MBR decreased significantly (P=0.04). In the DME group, the MBR in the retinal artery, retinal vein, ONH, and choroid decreased significantly (P=0.02, P=0.04, P<0.001, and P=0.04, respectively). In the DME group, pre-IVB MBR in the ONH was significantly correlated with post-IVB foveal thickness (R= -0.71, P=0.002). There was no such correlation in the BRVOME group in the ONH.

Conclusion: IVB had a suppressive effect on circulation in eyes with DME but not in those with BRVOME. This suggests that this noninvasive and objective biomarker may be a useful part of pre-IVB evaluations and decision-making in DME.

No MeSH data available.


Related in: MedlinePlus

Best-corrected visual acuity before and after intravitreal injection of bevacizumab.Notes: BCVA did not change significantly after 1 week or 1 month in the DME group (P=0.34) but did in the BRVOME group (P=0.049), with the most significant improvement being 1 week after IVB (P=0.03); Freidman test compared between three points pre-IVB, 1 week post-IVB, 1 month post-IVB; †P<0.05, scheffe’s paired comparison compares between groups, *P<0.05.Abbreviations: BCVA, best-corrected visual acuity; BRVOME, branch retinal vein occlusion-associated macular edema; DME, diabetic macular edema; IVB, intravitreal bevacizumab; logMAR, logarithm of the minimum angle resolution.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4061168&req=5

f1-opth-8-1119: Best-corrected visual acuity before and after intravitreal injection of bevacizumab.Notes: BCVA did not change significantly after 1 week or 1 month in the DME group (P=0.34) but did in the BRVOME group (P=0.049), with the most significant improvement being 1 week after IVB (P=0.03); Freidman test compared between three points pre-IVB, 1 week post-IVB, 1 month post-IVB; †P<0.05, scheffe’s paired comparison compares between groups, *P<0.05.Abbreviations: BCVA, best-corrected visual acuity; BRVOME, branch retinal vein occlusion-associated macular edema; DME, diabetic macular edema; IVB, intravitreal bevacizumab; logMAR, logarithm of the minimum angle resolution.

Mentions: BCVA and FT before and after IVB are shown in Figures 1 and 2, respectively. MBR in the retinal artery, retinal vein, ONH, and choroid before and after IVB is shown in Figure 3. In the DME group, MBR changed significantly in all regions 1 week and 1 month after IVB (retinal artery, P=0.02; retinal vein, P=0.04; ONH, P<0.001; and choroid, P=0.04). In the BRVOME group, MBR did not change significantly 1 week or 1 month after IVB in any of the measured regions (retinal artery, P=0.09; retinal vein, P=0.33; ONH, P=0.50), except the choroid (P=0.04).


The effect of intravitreal bevacizumab on ocular blood flow in diabetic retinopathy and branch retinal vein occlusion as measured by laser speckle flowgraphy.

Nitta F, Kunikata H, Aizawa N, Omodaka K, Shiga Y, Yasuda M, Nakazawa T - Clin Ophthalmol (2014)

Best-corrected visual acuity before and after intravitreal injection of bevacizumab.Notes: BCVA did not change significantly after 1 week or 1 month in the DME group (P=0.34) but did in the BRVOME group (P=0.049), with the most significant improvement being 1 week after IVB (P=0.03); Freidman test compared between three points pre-IVB, 1 week post-IVB, 1 month post-IVB; †P<0.05, scheffe’s paired comparison compares between groups, *P<0.05.Abbreviations: BCVA, best-corrected visual acuity; BRVOME, branch retinal vein occlusion-associated macular edema; DME, diabetic macular edema; IVB, intravitreal bevacizumab; logMAR, logarithm of the minimum angle resolution.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4061168&req=5

f1-opth-8-1119: Best-corrected visual acuity before and after intravitreal injection of bevacizumab.Notes: BCVA did not change significantly after 1 week or 1 month in the DME group (P=0.34) but did in the BRVOME group (P=0.049), with the most significant improvement being 1 week after IVB (P=0.03); Freidman test compared between three points pre-IVB, 1 week post-IVB, 1 month post-IVB; †P<0.05, scheffe’s paired comparison compares between groups, *P<0.05.Abbreviations: BCVA, best-corrected visual acuity; BRVOME, branch retinal vein occlusion-associated macular edema; DME, diabetic macular edema; IVB, intravitreal bevacizumab; logMAR, logarithm of the minimum angle resolution.
Mentions: BCVA and FT before and after IVB are shown in Figures 1 and 2, respectively. MBR in the retinal artery, retinal vein, ONH, and choroid before and after IVB is shown in Figure 3. In the DME group, MBR changed significantly in all regions 1 week and 1 month after IVB (retinal artery, P=0.02; retinal vein, P=0.04; ONH, P<0.001; and choroid, P=0.04). In the BRVOME group, MBR did not change significantly 1 week or 1 month after IVB in any of the measured regions (retinal artery, P=0.09; retinal vein, P=0.33; ONH, P=0.50), except the choroid (P=0.04).

Bottom Line: In the BRVOME group, there was no significant change in MBR in the retinal artery, retinal vein or ONH, but choroidal MBR decreased significantly (P=0.04).In the DME group, the MBR in the retinal artery, retinal vein, ONH, and choroid decreased significantly (P=0.02, P=0.04, P<0.001, and P=0.04, respectively).IVB had a suppressive effect on circulation in eyes with DME but not in those with BRVOME.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.

ABSTRACT

Background: This study evaluated the effect of intravitreal injection of bevacizumab (IVB) on macular edema associated with diabetic retinopathy (DME) or branch retinal vein occlusion (BRVOME) using laser speckle flowgraphy.

Methods: A comparative interventional study of 25 eyes from 22 patients with macular edema (DME group: 12 eyes; BRVOME group: 13 eyes) who underwent IVB. Mean blur rate (MBR) was measured in the retinal artery, retinal vein, optic nerve head (ONH), and choroid before and after IVB.

Results: In the BRVOME group, there was no significant change in MBR in the retinal artery, retinal vein or ONH, but choroidal MBR decreased significantly (P=0.04). In the DME group, the MBR in the retinal artery, retinal vein, ONH, and choroid decreased significantly (P=0.02, P=0.04, P<0.001, and P=0.04, respectively). In the DME group, pre-IVB MBR in the ONH was significantly correlated with post-IVB foveal thickness (R= -0.71, P=0.002). There was no such correlation in the BRVOME group in the ONH.

Conclusion: IVB had a suppressive effect on circulation in eyes with DME but not in those with BRVOME. This suggests that this noninvasive and objective biomarker may be a useful part of pre-IVB evaluations and decision-making in DME.

No MeSH data available.


Related in: MedlinePlus